NOL4L-DT: A Potential Drug Target for Cancer and Neurodegenerative Diseases

Target Name: NOL4L-DT

NCBI ID: G149950

NOL4L-DT

Other Name(s): NOL4L divergent transcript

NOL4L-DT: A Potential Drug Target for Cancer and Neurodegenerative Diseases

NOL4L-DT, or NOL4L divergent transcript, is a molecule that has been identified as a potential drug target or biomarker for the treatment of various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. NOL4L-DT is a long non-coding RNA molecule that has been shown to play a role in the regulation of gene expression in various organisms, including humans.

One of the key features of NOL4L-DT is its ability to interact with the RNA-protein complex, known as the RNA-protein interaction network (RPN). The RPN is a complex of RNA-protein interactions that plays a central role in regulating gene expression and is involved in the regulation of various cellular processes, including cell growth, differentiation, and apoptosis.

NOL4L-DT has been shown to interact with several key components of the RPN, including the protein stability and the RNA-binding module (RBM). The RBM is a key structural element of the RPN that is involved in the formation of the RNA-protein complex and has been shown to play a role in the regulation of various cellular processes, including cell growth, apoptosis, and translation.

In addition to its interaction with the RBM, NOL4L-DT has also been shown to interact with the protein encoded by the gene SNAP/KBP, which is involved in the regulation of DNA binding and protein-protein interactions.

The potential implications of these interactions are that NOL4L-DT may play a role in the regulation of gene expression and the regulation of cellular processes that are important for the development and progression of various diseases.

In the context of cancer, NOL4L-DT has been shown to be involved in the regulation of various cellular processes that are important for tumor growth and progression. For example, studies have shown that NOL4L-DT is involved in the regulation of cell cycle progression. , cell survival, and angiogenesis, which are all critical for the development and progression of cancer.

In addition to its role in cancer, NOL4L-DT has also been shown to be involved in the regulation of neurodegenerative diseases. For example, studies have shown that NOL4L-DT is involved in the regulation of neurotransmitter synthesis and release, which is important for the regulation of various neurological functions, including mood, attention, and learning.

In addition to its role in neurodegenerative diseases, NOL4L-DT has also been shown to be involved in the regulation of autoimmune disorders. For example, studies have shown that NOL4L-DT is involved in the regulation of immune cell function and the regulation of inflammation , which is important for the development and progression of autoimmune disorders.

In conclusion, NOL4L-DT is a molecule that has been shown to play a role in the regulation of gene expression and cellular processes in various organisms, including humans. The potential implications of these interactions are that NOL4L-DT may be a drug target or biomarker for the treatment of various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Further research is needed to fully understand the role of NOL4L-DT in these processes and to develop effective treatments.

Protein Name: NOL4L Divergent Transcript

The "NOL4L-DT Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about NOL4L-DT comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets